Tazemetostat Plus CHOP in 1L T-cell Lymphoma
Withdrawn · Phase 2 · NCT06692452
Conditions: Lymphoma, Peripheral T Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma
At a glance
- Research payments reported, 2025
- $140,000
- U.S. investigators named
- 1
- Sites paid
- 1
About the trial
- Sponsor
- Eric Jacobsen, MD (with Ipsen)
- Tested
- Tazemetostat (drug), Doxorubicin (drug), Vincristine (drug), Prednisone (drug), Cytoxan (drug), Carmustine (drug), Etoposide (drug), Cytarabine (drug), Melphalan (drug)
- Dates
- Started 2024-12-24; completion 2032-10-01
- Results posted
- Not yet
This research is being done to evaluate tazemetostat in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy as a possible treatment for peripheral T-Cell Lymphoma (PTCL). The name of the study drugs involved in this study are: * Tazemetostat (a type of inhibitor for Enhancer of Zeste Homolog 2 (EZH2)) * Standard of care CHOP therapy: * Cyclophosphamide (a type of alkylating agent) * Doxorubicin (a type of anthracycline antibiotic) * Vincristine (a type of vinca alkaloid) * Prednisone (a type of corticosteroid) * Standard of care BEAM conditioning regimen for autologous stem cell transplant: * Carmustine (a type of alkylating agent) * Eto…
From ClinicalTrials.gov, last updated 2026-04-01. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ipsen Biopharmaceuticals, Inc reported $140,000 in research payments for this study in 2025 (1 payments).
Products named: Tazverik
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Dana-Farber Cancer Institute $140,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.